HONG KONG, Feb. 2, 2024 /PRNewswire/ — Agilis Robotics, a leader in surgical robotics, is driving a paradigm shift in "incisionless" endoluminal surgery. The company's breakthroughs in highly miniaturized and flexible robotic instruments provide exceptional dexterity, enabling precise tissue resection within natural orifices. This innovation integrates seamlessly with standard endoscopes, reducing the learning curve and enhancing cost-effectiveness.
Agilis Robotics's system includes a primary cart, a compact control console, and disposable robotic arms, ensuring performance and sterility. Priced at less than 20% of conventional robotic systems, it offers a cost-effective solution for medical institutions. The system's adaptability spans the upper and lower gastrointestinal tract, urinary tract, throat, and gynaecology, offering unprecedented possibilities for endoluminal surgery.
Market Position and Demand
With the global surge in demand for endoluminal surgeries driven by increased cancer screening, Agilis Robotics is strategically positioned. Addressing over 3.5 million new GI cancer cases and 690k bladder cancer cases annually, the company aims to capture the underserved endoluminal surgery market. The system promises effective early-stage treatment with reduced procedure time and recurrence rates.
Funding and Development
As a spin-off from The University of Hong Kong, Agilis Robotics has secured over HKD 90 million in funding from private investors. These funds support further development and preparation for clinical trials. Six live animal studies have demonstrated promising results, with first-in-human trials targeted for the first half of 2024. Regulatory submissions to the FDA and NMPA mark significant milestones toward commercialization.
Financial Success and Leadership
Agilis Robotics's CFO, Hui Ka-Ming, emphasizes the company's success compared to "Chapter 18A" listed companies in the HKEX. With a focus on cost-effectiveness, marketability, and potential, the company aims to create a successful venture for investors and hospitals.